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Abstract: Metallothionein-3 (MT-3), a member of the mammalian metallothionein (MT) family,
is mainly expressed in the central nervous system (CNS). MT-3 possesses a unique neuronal growth
inhibitory activity, and the levels of this intra- and extracellularly occurring metalloprotein are
markedly diminished in the brain of patients affected by a number of metal-linked neurodegenerative
disorders, including Alzheimer’s disease (AD). In these pathologies, the redox cycling of copper,
accompanied by the production of reactive oxygen species (ROS), plays a key role in the neuronal
toxicity. Although MT-3 shares the metal-thiolate clusters with the well-characterized MT-1 and
MT-2, it shows distinct biological, structural and chemical properties. Owing to its anti-oxidant
properties and modulator function not only for Zn, but also for Cu in the extra- and intracellular
space, MT-3, but not MT-1/MT-2, protects neuronal cells from the toxicity of various Cu(II)-bound
amyloids. In recent years, the roles of zinc dynamics and MT-3 function in neurodegeneration are
slowly emerging. This short review focuses on the recent developments regarding the chemistry and
biology of MT-3.
Keywords: metallothionein-3; copper; zinc; metal-thiolate clusters; neurodegeneration; reactive
oxygen species; metal homeostasis; amyloid
1. Introduction
Aging, a major risk factor for neurodegenerative disorders, is accompanied with structural,
chemical, functional, neuropsychological, and genetic changes, with increased susceptibility to diseases
and cognitive impairments [1]. In the normal brain, a high concentration of essential transition
metal ions such as zinc, copper, and iron is present. The homeostasis of these transition metals is
tightly regulated and essential for brain physiology [2,3]. In physiological conditions, micromolar
concentrations of zinc and copper are actively released from neurons during neurotransmission
processes into pre- and postsynaptic clefts. However, in dysregulated metal metabolism, present in
neurodegenerative disorders, the ill-binding of copper and zinc to the disease specific amyloidogenic
peptides or proteins correlates with deposition of amyloid fibrils. Among the most prominent examples
are the Aβ peptides in Alzheimer (AD), α-synuclein in Parkinson (PD), prion protein in prion deposits
typical of Creutzfeldt–Jakob disease (CJD), and superoxide dismutase-1 (SOD-1) in amyotrophic lateral
sclerosis (ALS). In these diseases, copper, due to its reactivity with molecular oxygen (O2), generates
neurotoxic reactive oxygen species (ROS) such as superoxide, hydrogen peroxide, and hydroxyl
radicals [2,3].
In the central nervous system (CNS), the natural metal chelator metallothionein-3 (MT-3)
represents one of the major players in copper and zinc homeostasis. This protein occurs intra- and
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extracellularly and was found down-regulated in AD [4]. However, in contrast to the almost exclusive
expression of MT-3 in the CNS [5], the expression of MT-1/-2 isoforms are found in almost all organs.
Besides the differences in the expression pattern, the control of MT-3 expression also differs from
the MT-1/-2 isoforms. Thus, in marked contrast to the induction of MT-1/-2 biosynthesis by a
range of factors including glucocorticoids, cytokines, reactive oxygen species, and metal ions [6],
the expression of MT-3 is unresponsive to these inducers. However, the MT-3 gene was identified as
hypoxia-inducible in several human tissues. Here the induction of MT-3 in cultured human astrocytes
by hypoxia suggested that the protein may protect the brain from hypoxic damage [7]. Furthermore,
a similar hypoxic induction of the MT-3 gene in human adipocytes implied that the protein may
protect adipocytes from hypoxic damage [8]. In other studies, the question of whether the MT-3
and MT-1 isoforms possess different biological properties has been addressed using cultured kidney
cells that allowed constitutive expression of both isoforms. The studies revealed that under zinc
deficient conditions MT-3, but not MT-1 inhibited the cell growth [9]. The neuronal growth inhibitory
activity of MT-3 appears to be the most prominent biological property of this protein. In this regard,
an extracellular addition of MT-3, but not MT-1/-2 counteract the ability of AD brain extract to stimulate
survival and neuritic sprouting of cultured neurons [10,11]. Both the growth inhibitory activity and the
protective effect of solely MT-3 from the toxic effect of amyloid peptide Aβ1–40 [10] have been linked
to its possible role in the pathogenesis of AD. However, the bioactivity and the protective role of MT-3
in AD are functionally unrelated. An increased interest in the physiological and pathophysiological
processes in the human brain brought about an increased research into the understanding of the
structure and biology of MT-3. In recent years, the list of MT-3 functions suggesting its role not only
in the CNS but also outside of this organ, is steadily increasing. At present, there are a few reviews
on record dealing with the MT-1 through MT-3 isoforms [12–22]. This review focuses on the recent
advances in our knowledge regarding the structural/chemical and functional properties of MT-3 in
metal related biological processes.
2. Structural and Chemical Properties of Metallothionein-3
As recent publications cover the protective role of MT-3 in AD, and its possible role in lead
detoxification in the human brain, we wish to briefly summarize the current knowledge about the
structure and reactivity of the protein required to discuss these new reports. Since the bioactivity of
MT-3 in neuronal assays has been established for the native protein, containing both copper and zinc
ions, and for the recombinant human Zn7MT-3 [4,11,23], the structural features of both metalloforms
have been investigated (Table 1). The structural studies on recombinant MII7MT-3 revealed that, like the
MII7MT-1/-2 isoforms, the seven divalent metal ions are tetrahedrally coordinated through the array
of 20 conserved cysteines forming two metal-thiolate clusters, i.e., MII3(CysS)9 and MII4(CysS)11.
A MII3(CysS)9 metal-cluster is located in the N-terminal β-domain (residues 1–31) and a MII4(CysS)11
cluster is located in the C-terminal α-domain (residues 32–68) of MII7MT-3 [24,25]. In these clusters,
unprecedented dynamic processes exist. A fast exchange between conformational cluster substates and
very slow exchange processes between configurational cluster substates in the β-domain differentiate
MT-3 from other isoforms [26]. As a result, only the 3D structure of the C-terminal α-domain of
mouse and human 113Cd7MT-3, containing an adamantane-like Cd4Cys11 cluster, could be determined
by NMR measurements [27,28]. The structure of this domain reveals a peptide fold and cluster
organization very similar to that found in mammalian Cd7MT-1/-2 (Figure 1A).
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Table 1. Electronic absorption and luminescence properties of Zn7MT-3, Cd7MT-3,
and Cu(I)4Zn4MT-3 [26,29,30]. a ligand-to-metal-charge-transfer; b lifetime.
MT-3 Form
Absorption
Luminescence (77 K)
High-Energy Band Low-Energy Band
1st LMCT a
Band (nm)
λem
(nm)
τ b
(µs)
λmax Excitation
Spectra (nm)
λem
(nm)
τ
(µs)
λmax Excitation
Spectra (nm)
Zn7MT-3 ~230 - - - - - -
Cd7MT-3 ~250 - - - - - -
Cu(I)4Zn4MT-3 ~265 425 ~40 envelope < 350 565 ~135 ~265; ~300
Native MT-3, as isolated from human [4] and bovine [31] brains, contains four Cu(I) and between
three and four Zn(II) ions. The isolated Cu(I)4Zn3–4MT-3 is a monomeric protein that is stable in
air. Extended X-ray absorption fine structure (EXAFS) studies on the native protein revealed the
presence of two homometallic clusters, a Cu(I)4–thiolate cluster and a Zn3–4–thiolate cluster [31].
In contrast to tetrahedrally coordinated Zn(II) ions, Cu(I) ions are diagonally and/or trigonally
coordinated by two or three cysteine ligands [32]. The localization of both clusters in the protein
structure was established by the spectroscopic and immunochemical studies of Cu(I)4,Zn4MT-3.
Thus, the Cu(I)4–thiolate cluster is located in the N-terminal β-domain and the Zn4–thiolate cluster
in the C-terminal α-domain [22,33]. Based on the spectroscopic and luminescence properties of
air-stable Cu(I)4,Zn4MT-3 (Table 1), generated in the aerobic reaction between Zn7MT-3 and free Cu(II),
the presence of a Cu(I)4S5−x cluster containing five reduced thiolates and two disulfide bonds has been
postulated (Figure 1B) [29,30]. It may be noted that the adamantane-like {M4S6} polyhedron is the
most frequently observed species in copper-thiolate chemistry. Therefore, by analogy with inorganic
model complexes, besides the reduced cysteine thiolates the participation of a disulfide bridge sulfur
(indicated by x) in the Cu(I) coordination cannot be excluded.
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Figure 1. Metal-thiolate clusters in metallothionein-3. (A) The NMR solution structure of the Cd4-α-
domain of human Cd7MT-3. The Cd(II) ions are shown as light-orange spheres connected to the 
protein backbone by cysteine thiolate ligands. The model was generated with PyMOL using the 
Protein Data Bank coordinates of 2FJ5 [28]; (B) model of the Cu(I)4CysS5 cluster, derived from the 
spectroscopic characterization of Cu(I)4,Zn4MT-3 [29,30]. Metal ions are shown as dark gray spheres 
connected to cysteine sulfur ligands (yellow). 
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they bind in vivo. In some cases, metals are delivered to the metalloproteins by specialized 
metallochaperones. However, for most metalloproteins, a critical factor is the availability of the 
appropriate metal species in the buffered pools in the cell. In a number of studies, the Escherichia coli 
expression system was used to address the question regarding the in vivo metal-binding abilities of 
a number of MTs [34]. In this regard, the particular MT was first recombinantly expressed in E. coli 
cultures enriched with Zn(II), Cd(II), or Cu(II). Subsequently, ZnMT preparations were then titrated 
in vitro with Cd(II) or Cu(I) ions and the generated metalloforms analyzed. A comparison of the  
E. coli generated metalloforms with those formed in vitro was taken to indicate the metal binding 
preference of the particular MT. Based on such studies carried out on MT-3, it has been concluded 
that this MT isoform exhibits a marked Cu–thionein character, with a high tendency to coordinate 
Cu(I) ions [35]. In all these studies, a high degree of metal selectivity is discussed by the authors in 
terms of inherent properties of MTs. A critical assessment of this approach in assigning the metal 
selectivity of MTs in vivo has been given [35]. In this work, it has been put forward that all metals in 
the cell are present buffered to given concentrations, due to their binding to other proteins and low 
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A fundamental question about all metalloproteins is what determinants control which metals
they bind in vivo. In some cases, metals are delivered to the metalloproteins by specialized
metallochaperones. However, for most metalloproteins, a critical factor is the availability of the
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appropriate metal species in the buffered pools in the cell. In a number of studies, the Escherichia coli
expression system was used to address the question regarding the in vivo metal-binding abilities of
a number of MTs [34]. In this regard, the particular MT was first recombinantly expressed in E. coli
cultures enriched with Zn(II), Cd(II), or Cu(II). Subsequently, ZnMT preparations were then titrated
in vitro with Cd(II) or Cu(I) ions and the generated metalloforms analyzed. A comparison of the
E. coli generated metalloforms with those formed in vitro was taken to indicate the metal binding
preference of the particular MT. Based on such studies carried out on MT-3, it has been concluded
that this MT isoform exhibits a marked Cu–thionein character, with a high tendency to coordinate
Cu(I) ions [35]. In all these studies, a high degree of metal selectivity is discussed by the authors in
terms of inherent properties of MTs. A critical assessment of this approach in assigning the metal
selectivity of MTs in vivo has been given [35]. In this work, it has been put forward that all metals
in the cell are present buffered to given concentrations, due to their binding to other proteins and
low molecular weight compounds. The metal binding preference of a particular MT in E. coli cultures
implies that the metal selectivity reflects its structural properties. However, the E. coli cytosol still
contains other proteins and low molecular weight compounds contributing to the metal buffering.
Consequently, the exact maintenance of the ratios of buffered metal ions will dictate the correct metal
incorporation into a protein. Overall, it would appear that the binding of the correct metal into the
protein structure might be regulated by adjusting the ratios of buffered metal ions to different location
in various cell types [36]. A similar conclusion has been drawn from computational studies in which,
in the absence of metallochaperons, the local metal concentrations were found critical for the metal
specificity of proteins [37]. Although the enhanced copper-thionein character of MT-3 over MT-1/-2
may still, in part, reflect subtle differences between the two sequences and consequently their structural
properties [38], it would appear that the reported metal binding preference of various MTs in E. coli
cultures may not exactly reflect the buffered metal concentrations present in different mammalian cell
types where the MT biosynthesis occurs.
3. Metallothionein-3 in Metal-Linked Neurodegenerative Disorders
The protective role of MT-3 from AD pathology has been implicated based on the finding that the
protein (a) is down-regulated in AD, (b) shows extracellular growth inhibitory activity and antagonizes
the ability of AD brain extract to stimulate survival and neuritic sprouting, and (c) protects, by an
unknown mechanism, the neuronal cells from the toxic effect of amyloid peptide Aβ1–40 [4,5,10,11,39].
In an AD brain, Aβ forms amyloid plaques in specific regions in the brain, which have been considered
a key element in its pathogenesis [40–42]. Furthermore, a large body of evidence connects the
metal-induced aggregation of Aβ by transition metal ions copper and zinc and accompanied oxidative
stress with the disease progression [43]. In contrast to redox-inert zinc, redox-active copper aberrantly
bound to amyloidogenic Aβ peptides can activate molecular oxygen, resulting in the production of ROS
through Fenton and Haber–Weiss reactions [44]. In view of the observation that extracellular Zn7MT-3
protects the neuronal cells from the toxic effect of amyloid peptide Aβ1–40 [10,45], an interaction of free
Cu(II) and that bound in Cu(II)–Aβ1–40 with Zn7MT-3 has been found responsible for this protective
effect [30]. The spectroscopic and mass spectrometric studies on the interaction between free Cu(II)
and human Zn7MT-3 revealed that concomitant with the Cu(II) reduction to Cu(I) by the thiolate
ligands the monovalent copper is bound to the protein. As a result, an air-stable Cu(I)4Zn4MT-3
species is formed cooperatively in the β-domain together with two intramolecular disulfide bonds and
the release of three originally bound Zn(II) ions. Furthermore, the Cu(II)-mediated hydroxyl radical
production was fully abolished, indicating that the protein, through the formation of the redox-inert
Cu(I)4Zn4MT-3 structure, efficiently scavenges the free Cu(II) ions [30]. In the follow up studies,
the question as to the reported protective effect of human Zn7MT-3 against Aβ1–40 toxicity in neuronal
cell culture [10] has been addressed. The toxicity of Aβ1–40 stems mainly from the formed Cu(II)–Aβ1–40
complex in the extracellular space and its interaction with molecular oxygen, whereby the ROS are
generated. In vitro studies of the interaction between Cu(II)–Aβ1–40 and Zn7MT-3 established that the
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protein can efficiently remove Cu(II) from both the soluble and insoluble aggregates of Cu(II)–Aβ1–40.
The products of this reaction are the already discussed air-stable Cu(I)4Zn4MT-3 species and the
redox-inert Zn(II)–Aβ1–40 complex. In addition, the metal-swap between Zn7MT-3 and Cu(II)–Aβ1–40
fully abolishes the Cu(II)-mediated ROS production. This protective effect against the ROS toxicity has
been demonstrated not only by in vitro experiments but also in human neuroblastoma cell cultures [46].
The mechanism of exchange of metal ions between Zn7MT-3 and Cu(II)–Aβ1–40 was also investigated
by spectroscopy and transmission electron microscopy [47]. The studies revealed that metal ion
exchange occurs via free Cu(II) on a time scale of seconds to minutes and that metal ion exchange
induces time-dependent amyloidogenic structural and morphological changes in Aβ1–40 on a time
scale of hours. The morphological changes were primarily due to the binding of Zn(II) to Aβ1–40
aggregates [48]. Taken together, these studies corroborate a possible beneficial role of endogenous
MT-3 in protecting from the AD etiology. In vivo studies, investigating the function of MT-3 in double
transgenic mice presenting AD pathology (Tg2576 mouse AD model), support this role [49]. In a mouse
AD model, APP increases death rate and affects behavioral phenotype. The absence of MT-3 partially
reversed the APP-induced mortality and changes in the behavior of females. Furthermore, the amyloid
plaques formation and/or APP expression in the cortex and hippocampus of MT-3 deficient females
were decreased. Interestingly, MT-3 absence, on the one hand, substantially decreased APP in brain
homogenates from female mice and, on the other hand, shows a tendency to increase copper levels in
both genders [49].
In the later studies, the protective effect of the human Zn7MT-2A isoform against Cu(II)–Aβ1–40
toxicity was also investigated and compared with that of Zn7MT-3 [50]. The studies showed that MT-2A
can protect against copper-induced Aβ aggregation and neurotoxicity. However, in contrast to the
original studies employing Zn7MT-3, in which the formation of the air stable Cu(I)4Zn4MT-3 species
was found crucial for the protective effect [46], the underlying reaction between Cu(II)–Aβ1–40 and
Zn7MT-2A has been interpreted using the chemical characteristics of the fully reduced Cu(I)10MT-2A
and Cu(I)12MT-3 species. However, as the reduction of Cu(II) in Cu(II)–Aβ1–40 to Cu(I) is accomplished
by the thiolate ligands of Zn7MTs, the formation of fully reduced Cu(I)10MT-2A and Cu(I)12MT-3
in the oxidizing extracellular environment is unlikely. This conclusion is supported by the mass
spectrometric demonstration that the cysteine thiolates in Zn7MT-3 can reduce up to 8 Cu(II) [30]
concomitant with the formation of intramolecular disulfides. Thus, while the stepwise reduction of the
first 4 Cu(II) equivalents confirmed the cooperative formation of the air-stable Cu(I)4Zn4MT-3 species,
the reductions of the following Cu(II) equivalents resulted in the simultaneous presence of a number
of air-sensitive Cu(I)MT-3 species [30]. These studies signify the importance of Cu(I)4Zn4MT-3 for
its protective effect in AD. By contrast, in the studies of the interaction between Cu(II)–Aβ1–40 and
Zn7MT-2A, the direct metal swap between Zn(II), coordinated by thiolate ligands in Zn7MT-2A and
Cu(II), coordinated by nitrogen and oxygen ligands in Cu(II)–Aβ1–40, has been implicated and the
importance of metal affinities for the protective effect stressed [50]. However, the assumed direct metal
swap between Cu(II)–Aβ1–40 and Zn7MT-2A cannot occur without the preceding Cu(II) reduction to
Cu(I) by cysteine ligands. Accordingly, the differences in affinities are not essential for the protective
effect, but rather the long-term stability of partially oxidized Cu(I),ZnMT-2A formed upon Cu(II)
reduction and its removal from Cu(II)–Aβ1–40 in the oxidizing extracellular space. Thus, to gain an
insight into the protective effect of Zn7MT-2A the redox stability of different Cu(I)x, ZnyMT-2A species,
generated upon aerobic Cu(II) reduction, should be addressed.
The amyloid hypothesis in AD considers the Aβ production and deposition as the trigger of
this neurodegenerative disorder [51]. So far, the protective effect of Zn7MT-3 from the toxicity of
the Cu(II) containing Aβ1–40 and Aβ1–42 peptides has been described [46]. However, the proteolytic
cleavage of APP by β- and γ-secretase yields several other isoforms of the Aβ peptides. β-Secretase,
the β-site APP-cleaving enzyme 1 (BACE1), is an aspartyl protease [52–54], while γ-secretase is a
multiprotein complex consisting of at least four essential components (presenilin, nicastrin, Aph-1,
and Pen-2) necessary for full enzymatic activity [55]. The APP cleavage by β- and γ-secretase gives
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rise to Aβ1–42 and Aβ isoforms ranging from Aβ1–40 down to Aβ1–17 [56]. In addition, β-secretase
cleavage together with α-secretase cleavage yield several short Aβ peptides [55]. In this context, the
increased concentrations of Aβ1–16 have been found in sporadic AD (SAD) and familial AD (FAD)
compared to non-demented controls.
Apart from Aβ with aspartate (Asp1), as the first amino acid in Aβ1−x, several N-truncated
and modified Aβ peptides have been found in the brains of AD patients. However, to extract and
identify the exact levels of the various N-truncated Aβ variants in post-mortem brains is difficult
as many factors—such as antibody specificities, extraction protocols and brain areas studied—can
influence an analysis [57]. Nevertheless, there is general agreement that plaque-born peptides
harbor high amounts of N-truncated Aβ, especially that starting with Phe4. As revealed by detailed
analyses of Aβ isoform pattern in the cerebellum, cortex, and hippocampus of FAD subjects, SAD
subjects and non-demented controls, the dominating Aβ isoforms in AD brains are Aβ4–42, Aβ1–40,
and Aβ1–42 [58,59]. The first three amino acids (Phe-Arg-His) of N-truncated Aβ4–42 give rise to the
H2N-Xaa–Yaa–His– motif which enables a high affinity Cu(II) binding [60], already reported in human
serum albumin (HAS) [61]. Recently, the question regarding the Aβ4–42 affinity toward Cu(II) ions
has been addressed [62]. By using the Aβ4–16 peptide as a model to fully characterize the Cu(II)
binding properties, it was demonstrated that the Phe-Arg-His sequence of Aβ4–16 stoichiometrically
binds Cu(II) with a conditional Kd value of 30 fM at pH 7.4 (a conditional Kd is defined as the Kd at
pH 7.4). The determined affinity is more than three orders of magnitude higher than that reported for
Aβ1−x peptides (conditional Kd ∼1 × 10−10 M) [63]. Consequently, Aβ4–16 can compete successfully
with Aβ1−x peptides for Cu(II) ions. Furthermore, Aβ4–40/42 forms fibers twice as fast as Aβ1–42
with a very different morphology, forming bundles of very short amyloid rods. The generation of
ROS by Cu(II)–Aβ4–16, monitoring the hydroxyl radical production, revealed that the N-truncated
Cu(II)–Aβ4–16 and Cu(II)–Aβ4–42 species exhibit low levels of hydroxyl radical production compared
to Cu(II)–Aβ1–42. The results are in agreement with voltammetric experiments in which low level of
redox activity of the Cu(II)–Aβ4–16 complex was determined. Thus, Cu(II) in Cu(II)–Aβ4–16 could be
oxidized irreversibly to Cu(III), but could not be reduced to Cu(I) [62].
In view of the latter studies, the question has been addressed whether the N-terminal
Cu(II)–Aβ4–16 complex is fully resistant to the copper/zinc swap with Zn7MT-3 [64]. In marked contrast
to Cu(II)–Aβ1–16, no copper can be extracted from the N-truncated Cu(II)–Aβ4–16 complex by Zn7MT-3.
A reverse swap experiment, where apo–Aβ4–16 was added to the preformed Cu(I)/Zn(II)MT-3 complex,
was also conducted. Here the absence of Cu(I) transfer from MT-3 to the peptide reflects different
affinities of thiolate vs. oxygen and nitrogen ligands for Cu(I) ions. Conversely, addition of Cu(II)
ions to a mixture of Zn7MT-3 and apo–Aβ4–16 resulted in the partition of copper between these
biomolecules. From these studies, it has been concluded that Aβ4–42 and Zn7MT-3 may play parallel
roles in synaptic copper clearance in different synaptic settings [64].
Other naturally N-terminally truncated Aβ possessing the copper binding motif
H2N-Xaa–Yaa–His– is the Aβ11–40/42 peptide which starts with the residue Glu11. This peptide is
found in the cerebrospinal fluid and has a similar abundance to Aβ1–42, constituting one-fifth of
the plaque load [65]. A recent publication reported for Cu(II)–Aβ11–42 Kd of a 34 fM at pH 7.4 [66],
which is similar to 30 fM reported for Cu(II)–Aβ4–42. In this work, no studies regarding the redox
stability of the Cu(II)–Aβ11–42 complex and the peptide reactivity with Cu(II)–Aβ1–x or Zn7MT-3 have
been conducted [66]. Nevertheless, the N-truncated Aβ11–42 peptide may show a similar reactivity to
that reported for to the Aβ4–42 peptide (see above). However, although Aβ11–42 species with an intact
N terminus could be detected, the majority of peptides truncated at the N-terminal residue Glu11
are cyclized to pyroglutamate to generate pGlu-Aβ11–42 [67,68]. This peptide modification blocks the
Cu(II) coordination site.
Apart from the discovered protective effect of MT-3 in AD, its role in other metal-linked
neurodegenerative disorders like PD and prion disease has also been investigated. Similarly to AD,
the aberrant binding of Cu(II) to the amylogenic protein α-synuclein (α-Syn) in PD [69–71] and the
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prion protein in CJD [2] has deleterious effects in these diseases. These include the Cu(II)-mediated
ROS production and contribution to the formation of oligomers and fibrils. PD is characterized by the
loss of dopaminergic neurons and the formation of intracellular inclusions known as Lewy bodies,
composed mainly of aggregatedα-Syn in neurons of substantia nigra pars compacta [72]. The formation of
Cu(II)–α-Syn contributes to the progression of PD. In the pathogenesis of prion diseases, the structural
conversion of a natively folded prion protein (PrPC) [73], into a misfolded (PrPSc) is the key molecular
event [2,74]. While PrPC is mainly a helical monomeric protein, PrPSc is oligomeric and rich in β-sheet
structure [2]. The binding of up to six Cu(II) to the histidine residues present in the disordered part
of PrPC structure plays an important role in its conversion to PrPSc and thus the disease progression.
The studies of the interaction between Zn7MT-3 and Cu(II)-containing α-Syn and prion protein in vitro
revealed that Zn7MT-3, through copper subtraction and the formation of air-stable Cu(I)4Zn4MT-3,
plays a protective role [75,76]. Taken together, as the nature of the Cu(II) binding sites in Aβ, α-Syn,
and prion proteins substantially differ, the observed protective effect of Zn7MT-3 against Cu(II)
toxicity suggests that the protein may play a general protective role in metal-linked neurodegenerative
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Figure 2. Metal-swap reactions and Cu(II) redox-silencing by Zn7MT-3 in neurodegenerative disorders.
The protective effect of human Zn7MT-3 (with the structure of β-domain modeled by that of rat
Zn2Cd5MT-2 [77]) from the copper-mediated toxicity in AD, PD and prion diseases is summarized.
The metal swap between Zn7MT-3 and the disease specific amyloidogenic Cu(II)–Aβ1–40 peptide [46],
the Cu(II)–α-Syn [75] and Cu(II)–PrP proteins [76] abolishes the ROS production and the related cellular
toxicity. In this process, Cu(II) is reduced by the protein thiolates concomitant with its binding into
the N-terminal β-domain, forming the Cu(I)4Zn4MT-3 species and the non-redox-active Zn(II)–Aβ1–40,
Zn(II)–α-Syn and Zn(II)–PrP. In Cu(I)4Zn4MT-3 an air-stable Cu(I)4-thiolate cluster and two disulfide
bonds are present the N-terminal β-domain.
4. Toxicological and Neuropathological Aspects of Lead (Pb) Toxicity in Relation to
Mammalian Metallothioneins
The biosynthesis of most predominant mammalian isoforms MT-1/-2, but not of MT-3 is
upregulated in response to different stimuli, especially heavy metals, but also oxidative stress or
stress hormones (glucocorticoids). High cysteine content of MT-1/-2 (ca. 30%) confers them with a
high capacity to bind essential (Zn(II) and Cu(I)) and toxic (Cd(II), Ag(I), and Hg(II)) heavy metal
ions in vivo and in vitro. The exposure of humans or experimental animals to these metal ions lead
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to an induction of MT-1/-2 biosynthesis and the formation of MT-1/-2 metalloforms in which the
corresponding metal ion is bound. The mechanism of the metal-mediated induction of MT-1/-2
biosynthesis is discussed below. The role of MT-1/-2 in the heavy metal detoxification has been
established first for Cd(II) [78–82]. In recent years, there is an increased interest in understanding
of the toxicity of lead (Pb), a ubiquitous naturally occurring toxic metal. Pb-induced toxic effects
can manifest in several organs but the brain and kidney are primary targets. Compelling evidence
is emerging that Pb exposure, particularly in early-life, may cause neurodegeneration in later life
stages. The sporadic nature of AD argues for an environmental link that may drive AD pathogenesis.
In rodents, exposure to Pb during brain development predetermined the expression and regulation
of the APP, its amyloidogenic Aβ product and other AD-related genes in old age [83]. Life time
whole-body occupational Pb exposure has been recently shown to be a risk factor for PD [84]. Since
the formation of Lewy bodies in PD required MT-1/-2, the interaction between α-Syn and MT-1/-2
has been established using MT-null and wild-type cell lines [85]. A direct interaction between α-Syn
and MT-1/-2 was confirmed by antibody pull-down assay [86]. However, a similar study using the
MT-3 isoform has not been undertaken.
By analogy to the MT-1/-2 induction by Cd(II), the formation of mammalian Pb(II)MT-1/-2 in a
similar detoxification process has been anticipated. However, so far no Pb(II)-containing MTs have
been isolated and characterized from natural sources. Nevertheless, the in vitro characterization of
the Pb(II)-containing MT-1/-2 and MT-3 isoforms has been reported [87,88]. Prior to the discussion
of the structural features of these Pb(II)-containing MTs, the current knowledge regarding the
nature of low molecular weight Pb(II)-binding proteins, obtained upon the Pb(II) administration
to experimental animals, will be briefly discussed. Apart from these proteins, the heme pathway
enzyme δ-aminolevulinic acid dehydratase (ALAD) isoforms (240–280 kDa proteins), have attracted
the greatest attention as the enzymes are both inhibited and induced by lead (reviewed in [89]).
From a number of studies, the nature of low molecular weight proteins appears to be uncertain as
the occurrence of either low molecular weight lead-binding proteins or MT-like proteins have been
reported [89]. At this point, it should be noted that in all instances, no full characterization of these
proteins has been carried out. Lead-binding proteins are a series of low molecular weight proteins
(10 to 12 kDa) which have the capacity to bind and sequester lead in a nontoxic form in several
organs (kidney, brain, lung, liver, and erythrocyte). These proteins are rich in aspartate and glutamate
amino acids and possess a dissociation constant Kd for Pb(II) on the order of 10−8 M and appear to
normally bind zinc [90]. The occurrence of low molecular weight Pb(II)-binding protein(s) with a large
percentage of cysteine and a greater UV absorbance at 254 than at 280 nm, features diagnostic of a
MT, have also been reported [91]. In this regard, it has been shown that depending on the conditions
of Pb(II) administration to experimental animals the gel filtration fractions containing only ZnMT,
both PbMT and ZnMT metalloforms, or the metal mixed Pb,ZnMT form have been identified [89].
These observations can be explain, in part, by the underlying mechanism of the detoxification process
described for Cd(II) [92]. A hallmark of the promoters/enhancers of most MT genes are short DNA
sequence motifs termed metal response elements (MREs); many also harbor antioxidant response
elements (AREs) and glucocorticoid response elements (GREs) [93]. Transcriptional induction of
MT-1/-2 genes is mediated by the metal-regulatory transcription factor 1 (MTF-1) [92,94]. This protein
is essential not only for zinc-induced transcription of MT-1/-2 genes, but also for their induction by
other heavy metals like cadmium and copper and/or oxidative stress [92]. In the induction process,
MTF-1, upon activation with zinc displaced from zinc-saturated Zn7MT-1/-2 in the cytosol by cadmium
or copper binding, translocate from the cytosol to the nucleus where it binds to promoter proximal
MREs [94,95]. Lead, similarly to cadmium and copper, will also displace Zn(II) from Zn7MT-1/-2
and activate MTF-1. Consequently, depending on the experimental conditions the newly synthetized
thionein (the metal-free form of MT-1/-2) may then bind with different metal ions reflecting the
concentration of buffered metals available at folding (see above). It may be noted that although similar
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MREs and other DNA sequence motifs were also identified in the MT-3 gene, the MT-3 biosynthesis
was unresponsive to these inducers [39].
The spectroscopic/biochemical studies on the in vitro interaction of Pb(II) with MT-2 and MT-3
have been carried out and the Pb(II)-MT forms characterized [87,88]. In the structure of MII7MTs,
the divalent metal ions Zn(II) and/or Cd(II) are tetrahedrally coordinated by four cysteine sulfurs.
Recent structural studies aimed at the understanding of Pb(II) binding to thiol-rich structural proteins
containing zinc-binding sites. The studies showed that although zinc is bound tetrahedrally, Pb(II)
shows a clear preference for a three-coordinate Pb(II)-S3 mode. In the latter structure, Pb(II) is
coordinated by three sulfurs in a trigonal pyramidal geometry with the Pb 6s2 lone-pair electrons
occupying the axial position [96]. It has been concluded, moreover, that Pb(II) assumes a preferred
coordination mode of Pb-S3 even when an additional thiolate ligand is available for binding. The
interaction of Pb(II) with MT-2 has been studied by combination of spectroscopic and computational
methods [87]. By contrast to Zn(II) and Cd(II), the binding of Pb(II) results in the formation of
two different Pb7MT-2 complexes depending on the pH employed. The first complex, designated
Pb7MT-2(I), is formed under neutral conditions and the second, Pb7MT-2(II), under weakly acidic
(pH 4.5) conditions, The characterization of Pb7MT-2(I) revealed that all seven Pb(II) ions are trigonally
coordinated by three cysteine sulfurs (Pb–S3 mode) and that no metal-ligand ring in the α- or β-domain
is present. The marked structural differences to the cluster structure in Zn(II)- and Cd(II)-containing
MII7MTs results from the Pb 6s2 lone-pair electrons, which disrupt the tetrahedral coordination by
occupying the axial position. In the case of Pb7MT-2(II), completely different binding modes from
Pb7MT-2(I) exist with all cysteine ligands coordinating in the terminal form. These binding modes
include the trigonal pyramidal Pb–S3 mode, the distorted trigonal pyramidal Pb–S2O1 mode in the
α-domain, and the distorted quadrilateral pyramidal Pb–S3O1 in the β-domain.
The binding of Pb(II) and Zn(II) to MT-3 has been studied by isothermal titration calorimetry
(ITC), a technique capable of measuring the thermodynamics of metal binding [88]. Anaerobic ITC
measurements of Pb(II) displacing Zn(II) from Zn7MT-3 and experiments in which EDTA was used
to chelate metal ions from both Pb7MT-3 and Zn7MT-3 revealed that (i) MT-3 binds Pb(II) with a
higher affinity than it does Zn(II) and that Pb(II) displaces bound Zn(II) in Zn7MT-3 and that (ii) EDTA
extracted both metal ions from Zn7MT-3 and Pb7MT-3 in a tri-phasic process, indicating that they bind
to the protein in three populations with different binding thermodynamics. These data indicate that
Pb(II) binding to both apoMT-3 and Zn7MT-3 is thermodynamically favorable [88]. Overall, despite
the number of toxicological studies over many years, the in vivo interaction of MTs with Pb(II) is not
entirely clear.
5. Concluding Remarks
Since the initial discovery of MT-3 in normal human brains by Uchida et al. 1991 [4], the functional
role of this metalloprotein has been investigated intensively. MT-3 is involved in homeostasis of
essential transition metals zinc and copper in the brain. The amyloid-forming diseases such as AD,
PD, ALS, and prion (CJD) represent a group of neurodegenerative disorders that affect both animals
and humans. In these diseases, the role of metal ions, especially copper and zinc, is the subject of
intense research. Their involvement in protein misfolding, aggregation and in the generation of
reactive oxygen species have been shown. The structural and biological studies also show that these
metal ions not only bind to the disease specific amyloidogenic peptides or proteins with high affinity,
but also modify their biochemical properties, making them important players in the progression of
the disease. The protective effect of MT-3 from the copper toxicity has been demonstrated for AD,
PD, and prion diseases (see above). The neuroprotective effect of MT-3 in the pathogenesis of ALS
has also been established. In this work, MT-3 prevents the loss of motor neurons of ALS model
mice and prolongs the life span, even when the administration is started at the time of onset [97].
Furthermore, recent biological data reveal that MT-3 contributes to neuronal and astrocytic cell death
through zinc release [98] and that its interaction with actin modulates c-Abl signaling in astrocytes;
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c-Abl is a member of the nonreceptor tyrosine kinase family [99]. In addition, the observed developed
obesity in male MT3-null mice is due likely to abnormal leptin signaling in the hypothalamus [100].
Apart from the CNS, the MT-3 expression is also observed in a few non-CNS areas, including the
pancreas [101], prostate, testis, and tongue [102]. In this regard, more recent studies on the zinc-rich
insulin producing islet β-cells suggest a role for MT-3 in streptozotocin (STZ)-induced islet cell death
and consequent hyperglycemia [103]. Thus, it has been demonstrated that MT-3 may through PDE3a
(phosphodiesterase 3A) play a key role in zinc dyshomeostasis and cell death in STZ-treated islets.
Overall, the list of MT-3 functions, suggesting its role not only in the CNS, but also outside of this
organ, is steadily increasing.
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Abbreviations
Aβ Amyloid-beta
AD Alzheimer’s Disease
ALAD δ-aminolevulinic acid dehydratase
ALS Amyotrophic lateral sclerosis
APP Amyloid precursor protein
AREs Antioxidant response elements
BACE Beta-secretase
CJD Creutzfeldt–Jakob disease
CNS Central nervous system
EXAFS Extended X-ray absorption fine structure
FAD Familiar Alzheimer’s Disease
GREs Glucocorticoid response elements
ITC Isothermal Titration Calorimetry
MRE Metal response elements
MT Metallothionein
MTF-1 Metal-regulatory transcription factor 1
PD Parkinson’s Disease
PrP Prion Protein
PSEN1 Presenilin 1
PSEN2 Presenilin 1
SAD Sporadic Alzheimer’s Disease
SOD Superoxide Dismutase
α-Syn Alpha-Synuclein
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